AngioDynamics Future Growth
Future criteria checks 0/6
AngioDynamics is forecast to grow earnings and revenue by 76.3% and 4.4% per annum respectively while EPS is expected to grow by 73.8% per annum.
Key information
76.3%
Earnings growth rate
73.8%
EPS growth rate
Medical Equipment earnings growth | 18.3% |
Revenue growth rate | 4.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 05 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
5/31/2026 | 314 | -11 | N/A | N/A | 1 |
5/31/2025 | 287 | -43 | N/A | N/A | 4 |
5/31/2024 | 287 | -194 | N/A | N/A | 4 |
2/29/2024 | 324 | -192 | -23 | -17 | N/A |
11/30/2023 | 330 | -14 | -7 | -3 | N/A |
8/31/2023 | 336 | 6 | -5 | -1 | N/A |
5/31/2023 | 339 | -52 | -4 | 0 | N/A |
2/28/2023 | 335 | -37 | -12 | -7 | N/A |
11/30/2022 | 328 | -33 | -22 | -17 | N/A |
8/31/2022 | 321 | -33 | -28 | -23 | N/A |
5/31/2022 | 316 | -27 | -11 | -7 | N/A |
2/28/2022 | 306 | -40 | -7 | -4 | N/A |
11/30/2021 | 303 | -38 | 7 | 11 | N/A |
8/31/2021 | 298 | -34 | 16 | 21 | N/A |
5/31/2021 | 291 | -32 | 19 | 24 | N/A |
2/28/2021 | 273 | -169 | 10 | 16 | N/A |
11/30/2020 | 271 | -171 | -14 | -8 | N/A |
8/31/2020 | 268 | -170 | -21 | -13 | N/A |
5/31/2020 | 264 | -167 | -22 | -15 | N/A |
2/29/2020 | 277 | -7 | 0 | 7 | N/A |
11/30/2019 | 273 | -6 | 27 | 33 | N/A |
8/31/2019 | 273 | -7 | 36 | 40 | N/A |
5/31/2019 | 271 | -11 | 34 | 37 | N/A |
2/28/2019 | 205 | -34 | 33 | 36 | N/A |
11/30/2018 | 223 | -16 | 28 | 32 | N/A |
8/31/2018 | 240 | -12 | 26 | 29 | N/A |
5/31/2018 | 262 | -6 | 38 | 41 | N/A |
2/28/2018 | 343 | 1 | 33 | 37 | N/A |
11/30/2017 | 345 | -10 | N/A | 47 | N/A |
8/31/2017 | 347 | 4 | N/A | 51 | N/A |
5/31/2017 | 270 | -7 | N/A | 56 | N/A |
2/28/2017 | 356 | -25 | N/A | 55 | N/A |
11/30/2016 | 358 | -27 | N/A | 53 | N/A |
8/31/2016 | 357 | -42 | N/A | 48 | N/A |
5/31/2016 | 351 | -44 | N/A | 45 | N/A |
2/29/2016 | 347 | -1 | N/A | 37 | N/A |
11/30/2015 | 346 | -6 | N/A | 37 | N/A |
8/31/2015 | 349 | -5 | N/A | 25 | N/A |
5/31/2015 | 352 | -3 | N/A | 26 | N/A |
2/28/2015 | 356 | -4 | N/A | 25 | N/A |
11/30/2014 | 358 | 5 | N/A | 12 | N/A |
8/31/2014 | 354 | 4 | N/A | 23 | N/A |
5/31/2014 | 351 | 2 | N/A | 25 | N/A |
2/28/2014 | 346 | 2 | N/A | 26 | N/A |
11/30/2013 | 340 | -3 | N/A | 37 | N/A |
8/31/2013 | 340 | 0 | N/A | 40 | N/A |
5/31/2013 | 340 | -1 | N/A | 27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UG2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: UG2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: UG2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: UG2's revenue (4.4% per year) is forecast to grow slower than the German market (5.5% per year).
High Growth Revenue: UG2's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if UG2's Return on Equity is forecast to be high in 3 years time